Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity

RBC Capital initiated coverage on Bicycle Therapeutics PLC BCYC, noting an advantage in oncology and beyond.

The analyst writes the company’s lead program, Zelenectide pevedotin (zele, formerly BT8009), shows potential to compete in metastatic urothelial cancer (mUC) due to similar objective response rates and fewer adverse events compared to Pfizer Inc’s PFE Seagen Inc. drug, Padcev.